Figures computed from official regulatory filings — .
Analysttarget 8.56 USD (+520%) · consensus 4.89/5 · 9 buy · 0 hold · 0 sell
Ownershipinsiders 16% · institutions 65.76% · short 10.1% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Equillium, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Market information source · Oct 19, 2026
SEC company identity · Oct 19, 2026
Open-market timeline · full history
51 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Zedelmayer Christine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Connelly Stephen | Sell | $632.8K | SEC |
| Connelly Stephen | Sell | $91.1K | SEC |
| Zedelmayer Christine | Exercise | $11.4K | SEC |
| Zedelmayer Christine | Sell | $42.7K | SEC |
| Tom Penny | Sell | $191.8K | Unusual size | SEC |
| Zedelmayer Christine | Exercise | $37.4K | SEC |
| Zedelmayer Christine | Sell | $542 | SEC |
| Troupin Barbara | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zedelmayer Christine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tom Penny | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zedelmayer Christine | Exercise | $5.3K | SEC |
| Zedelmayer Christine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zedelmayer Christine | Sell | $150.1K | SEC |
| Zedelmayer Christine | Exercise | $7.6K | SEC |
| McDermott Charles Douglas | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| DEMSKI MARTHA Jtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zedelmayer Christine | Sell | $26.5K | SEC |
| Zedelmayer Christine | Exercise | $12.3K | SEC |
| Pruzanski Mark | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zedelmayer Christine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BRADBURY DANIELtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zedelmayer Christine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zedelmayer Christine | Sell | $90K | SEC |
| Zedelmayer Christine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |